FDA advisers endorse J&J's canagliflozin for diabetes

01/10/2013 | Wall Street Journal, The

An FDA panel recommended the approval of Johnson & Johnson's Invokana, or canagliflozin to treat type 2 diabetes in a 10-5 vote. Some advisers suggested that patients with impaired kidneys should be told not to take the drug.

View Full Article in:

Wall Street Journal, The

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel, Regulatory FDA
Cardinal Health
Columbus, OH
Assistant General Counsel
Cardinal Health
Columbus, OH
Regulatory Affairs Specialist
Stryker
Mahwah, NJ
Sr. Principal OptoMechanical Engineer - 14000008M2
Abbott
San Jose, CA
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA